Fig. 4: Patient stratification as defined by visual scoring and PD-L1 QCS in the Durvalumab and SoC arm of MYSTIC. | npj Precision Oncology

Fig. 4: Patient stratification as defined by visual scoring and PD-L1 QCS in the Durvalumab and SoC arm of MYSTIC.

From: Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC

Fig. 4

Kaplan–Meier analysis (OS) indicating subgroup stratification performance of TC scores at 1%, 25% and 50% cut-point together with QCS-PMSTC ≥ 0.575%. The p-values are derived from log-rank tests (p) or obtained for Cox interaction terms (pinteract).

Back to article page